Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Sclerosis-Relapsing-Remitting Clear all
Completed No phase listed Observational Accepts healthy volunteers

Mechanistic Studies of Teriflunomide in RRMS

NCT03464448
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Teriflunomide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 27, 2026, 4:36 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

NCT02881567
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
Daclizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Tampa, Florida • Des Moines, Iowa • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 27, 2026, 4:36 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions
Tovaxin
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 27, 2026, 4:36 AM EDT
Enrolling by invitation Phase 4 Interventional

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

NCT06495593
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 27, 2026, 4:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

NCT00391352
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
IFN-β-1a (Rebif®)
Drug
Lead sponsor
Waukesha Memorial Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

NCT00071838
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 27, 2026, 4:36 AM EDT
Completed No phase listed Observational

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

NCT06127095
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

Effects of Acthar on Recovery From Cognitive Relapses in MS

NCT02290444
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 27, 2026, 4:36 AM EDT
Enrolling by invitation Not applicable Interventional

Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery

NCT06641271
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Interventions
Closed Loop Trans-Auricular Vagus Nerve Stimulation System, Placebo
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 27, 2026, 4:36 AM EDT
Not yet recruiting Not applicable Interventional

Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis

NCT07724093
View directory record Official record
Conditions
Multiple Sclerosis (MS) Relapsing Remitting
Interventions
Powered Hip Flexion Orthosis (Hypershell X)
Device
Lead sponsor
University of Dayton
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Not applicable Interventional Results available

Assessing Tolerability of Avonex Intramuscular Injections

NCT01641120
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex
Drug
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 27, 2026, 4:36 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT02222948
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Vatelizumab, Placebo (for Vatelizumab)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Phase 3 Interventional

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

NCT00099502
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2008 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Wahls Paleo Diet and Progressive Multiple Sclerosis

NCT01915433
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Wahls Paleo Plus, Wahls Diet
Other
Lead sponsor
Terry L. Wahls
Other
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 27, 2026, 4:36 AM EDT
Withdrawn No phase listed Observational

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

NCT02419638
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Photobiomodulation Therapy in Persons With Multiple Sclerosis

NCT03691766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Photobiomodulation Therapy, Placebo
Other
Lead sponsor
Marquette University
Other
Eligibility
20 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 27, 2026, 4:36 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

NCT01963611
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg, Plovamer acetate 10 mg, Plovamer acetate 20 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
35
States / cities
Redding, California • San Diego, California • Fairfield, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 27, 2026, 4:36 AM EDT
Terminated Phase 3 Interventional Results available

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

NCT01633112
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
fingolimod, glatiramer acetate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
101
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 27, 2026, 4:36 AM EDT
Active, not recruiting No phase listed Observational

Serum Neurofilament Light in Multiple Sclerosis

NCT06282081
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions
Serum Neurofilament Light
Diagnostic Test
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT02555215
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 27, 2026, 4:36 AM EDT
Not listed Phase 4 Interventional

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

NCT04048577
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dosing Interruption of Natalizumab
Drug
Lead sponsor
Berkovich, Regina MD, PhD Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 27, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

NCT00324506
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (CellCept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 27, 2026, 4:36 AM EDT